Stem Cells

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
星期四, 五月 9, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Mantle cell lymphoma, Cancer, International Society, Investment, Cell, Phenotype, Safety, Risk, Pharmacokinetics, Poster, Lymphoproliferative disorders, Depreciation, Cytokine, Partnership, Lymphoma, Biologics license application, ATRA, Follicular lymphoma, CD19, ASH, Epstein–Barr virus, Patient, NHL, LD, Toxicity, BLA, Memory, Workforce, EBV, Biomarker, SLE, Tabelecleucel, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  • “This is anticipated to provide multiple near-term clinical milestones for ATA3219, including initial non-Hodgkin’s lymphoma data expected in the fourth quarter 2024, and initial lupus nephritis data in the first half of 2025, with plans to expand into a new SLE cohort without lymphodepletion.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Retrieved on: 
星期四, 五月 9, 2024
Stem Cells, Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Hospitals, Science, Clinical Trials, Multiple myeloma, Safety, Food, IND, Patient, SOC, Standard of care, BCMA, Investigational New Drug, Pharmaceutical industry

Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.

Key Points: 
  • Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.
  • Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
  • The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year.
  • In addition, the completion of the technical transfer to Kite allowed us to accelerate our development program and launch iMMagine-3 globally, which will enable broader and earlier patient access to anito-cel.”

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
星期四, 五月 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

Arcellx Provides First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
Oncology, Health, Stem Cells, Genetics, Pharmaceutical, Biotechnology, Collaboration, Research, Lonza, Cancer, Kite, Patient, Pharmaceutical industry

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.
  • As of March 31, 2024, Arcellx had cash, cash equivalents, and marketable securities of $691.0 million.
  • Collaboration revenue were $39.3 million and $17.9 million for the quarters ended March 31, 2024 and 2023, respectively, an increase of $21.4 million.
  • Net loss was $7.2 million and $27.3 million for the quarters ended March 31, 2024 and 2023, respectively.

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

Retrieved on: 
星期三, 五月 8, 2024
Radiology, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hospitals, Genetics, Data Management, Stem Cells, Science, Practice Management, Technology, Clinical Trials, Medical Supplies, FDA, Biotechnology, Surgery, Health, CO, Cancer, Depreciation, Webcast, DdPCR, Forecasting, Growth, MSKCC, Net operating loss, Patient, COVID-19, Acquisition, Adjustment, AACR, Bank statement, EGFR, GAAP, AstraZeneca

In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.

Key Points: 
  • In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
  • Our team is off to a strong start, helping to impact more patients every quarter in the large and underserved lung nodule diagnostic testing market.
  • Record quarterly gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023.
  • The Company reaffirms its 2024 financial outlook and expects to generate between $65 million and $68 million in total revenue in 2024.

Precision BioSciences to Report First Quarter Results on May 13, 2024

Retrieved on: 
星期二, 五月 7, 2024
FDA, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Gene editing, Precision BioSciences

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Induced Pluripotent Stem Cell (iPSC) Industry Market Size, Trends, and Forecast Report - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 7, 2024
Health, Stem Cells, OA, Cellular Dynamics International, University, Microsoft Exchange Server, Cell, CRISPR, Safety, Drug development, Osteoarthritis, World Games, MSC, Partnership, Research, CLI, B cell, Application, Disease, Human, Therapy, Patient, COVID-19, Tissue engineering, Graft-versus-host disease, IPSC, Medicine, Kyoto University, 3D bioprinting, Macular degeneration, Regenerative medicine, CDI, Clinical trial, Toxicology, Drug discovery, Personalized medicine, Merck, Thermo Fisher Scientific, Pharmaceutical industry

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
    Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development.

NIH Awards Hesperos Research Grant to Develop Animal-Free Botox Testing Platform

Retrieved on: 
星期二, 五月 7, 2024
Health, FDA, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, NMJ, NIH, Safety, Food, Cell, Animal, Acetylcholine, Spasticity, Botulinum toxin, MLB, Santhanam, Neurotoxin, Brain cell, Strabismus, Biology, Paralysis, Drug development, NCATS, Migraine, Drug discovery, Neuromuscular junction, Pharmaceutical industry

The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.

Key Points: 
  • The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.
  • Despite its therapeutic benefits, BoT is one of the most potent neurotoxins known to man, necessitating stringent batch testing to ensure consistent potency.
  • By successfully developing a high-throughput, human-based platform, Hesperos endeavors to obviate the need for animal testing in this process while simultaneously enhancing the safety profile of BoT.
  • https://fda.gov
    The mission of National Center for Advancing Translational Sciences (NCATS) at NIH is to turn research observations into health solutions through translational science.

Colossal Biosciences’ Thylacine Gene-Editing Technologies Provide Hope for Australia’s Endangered Northern Quoll

Retrieved on: 
星期三, 五月 8, 2024
Research, Environmental Issues, Environmental Health, Environment, University, Genetics, Education, Science, Biotechnology, Stem Cells, Other Science, Health, Leg, School, Organization, Deakin University, Curtin University, Ecosystem, Cell, CRISPR, Fibroblast, Colossal Biosciences, Convulsion, Risk, Genetic engineering, De-extinction, Saliva, Animal, Survival, Death, University of Melbourne, Gene editing, Doctor of Philosophy, Rhinella, Ecology, Life, Vertebrate, Food, Invertebrate, IPSC, Neurotoxin, Multimedia, Paralysis, Snake, Quoll, Reptile, Hunting

Since the introduction of invasive cane toads (Rhinella marina) in Queensland in the 1930s, the northern quolls have seen their populations plummet by 75% .

Key Points: 
  • Since the introduction of invasive cane toads (Rhinella marina) in Queensland in the 1930s, the northern quolls have seen their populations plummet by 75% .
  • Cane toads have now become an attractive food source for the northern quoll, which is especially vulnerable to the toad’s neurotoxins.
  • “It’s thrilling to see our de-extinction work for the Thylacine providing technology solutions for living endangered marsupials,” said Sara Ord, Director of Species Restoration at Colossal.
  • Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth.

Bio-Rad Reports First-Quarter 2024 Financial Results

Retrieved on: 
星期二, 五月 7, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Acquisition, Table, Webcast, Bank statement, Forecasting, Nature, GAAP, Growth, EPS, Bio-Rad Laboratories, Bank

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • Management will discuss the company’s first quarter 2024 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on May 7, 2024.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.